BenevolentAI

What BenevolentAI does

BenevolentAI is a clinical-stage AI drug discovery company that builds and applies a proprietary artificial intelligence platform to identify novel drug targets, design molecules, and repurpose existing drugs. The company's core technology is a decade-invested biomedical knowledge graph combined with proprietary ontologies that structure relationships across scientific literature, clinical data, patents, and other biomedical sources. The platform supports workflows from target identification through clinical candidate selection and is positioned to address structural inefficiencies in pharmaceutical R&D, including per-drug development costs exceeding $2 billion, timelines of 12-15 years, and clinical trial failure rates above 90%. BenevolentAI's most prominent real-world validation was its identification of baricitinib as a COVID-19 therapeutic, which subsequently received FDA Emergency Use Authorization.

The company serves pharmaceutical and biotechnology companies through strategic collaborations and co-development partnerships, and also operates its own internal pipeline. Named partners include AstraZeneca, with whom BenevolentAI is applying its platform to respiratory and cardiovascular disease, and the Institute of Cancer Research, with whom it identified drug combinations for DIPG brain cancer. BenevolentAI's monetization model is not publicly disclosed but is consistent with industry norms for clinical-stage AI biotechs: upfront and milestone-based collaboration revenue from pharma partners, with optional downstream royalties on partnered programs. The company operates through wholly-owned subsidiaries in the UK (London, Cambridge), the United States, and is domiciled in Luxembourg as a société anonyme.

BenevolentAI was founded in 2013 and raised approximately $292 million in disclosed equity funding across rounds in 2015, 2018, and 2019, with Temasek leading the most recent disclosed round. The company was previously publicly listed on Euronext Amsterdam under the ticker BAI. In March 2025, BenevolentAI delisted from Euronext Amsterdam and merged with Osaka Holdings S.à r.l., becoming a privately held entity following shareholder approval at an Extraordinary General Meeting. Prior to this transaction, the company experienced clinical setbacks and restructuring amid broader sector pressure on AI drug discovery valuations.

Name

BenevolentAI

Legal name

BenevolentAI

Website

https://benevolent.com

Company type

Private

Founded year

2013

Operating status

Acquired

Headcount range

251–500 employees

Short description

BenevolentAI is a clinical-stage AI drug discovery company that applies a proprietary knowledge graph and machine learning platform to drug target identification, molecule design, and repurposing for pharmaceutical and biotechnology partners.

Ownership category

akta.pro rank

Product category

AI-Enabled Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Prepackaged Software (7372)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• AI drug discovery
• Pharmaceutical research
• Biotechnology platforms
• Target identification
• Drug repurposing

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Infrastructure, Operations

Core offering

BenevolentAI builds and operates an AI-powered drug discovery and life science intelligence platform centered on a decade of investment in a proprietary knowledge graph and ontologies. The platform integrates scientific literature, clinical data, and patents to support target identification, molecule design, drug repurposing, and clinical candidate selection for pharmaceutical and biotechnology partners.

Product overview

BenevolentAI offers a unified AI drug discovery platform centered on its proprietary knowledge graph and ontology system. The platform is described as a next-generation life science intelligence solution that enables scientists and researchers to leverage cutting-edge AI and machine learning across drug discovery and development workflows. The system integrates diverse biomedical data sources to support complex R&D decisions from target identification through clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

• BenevolentAI Platform An AI-powered drug discovery and life science intelligence platform that integrates a knowledge graph and proprietary ontologies to support target identification, molecule design, drug repurposing, and clinical candidate selection for pharmaceutical and biotechnology partners across the R&D pipeline.

Quantifiable outcome

• BenevolentAI identified Baricitinib for COVID-19 which received FDA Emergency Use Authorization
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Partnerships

Three partnerships are on record, tiered core.

• AstraZenecacoreStrategic or Co-development Partner · 24 November 2025BenevolentAI collaborated with AstraZeneca to apply AI to target respiratory and cardiovascular conditions, combining BenevolentAI's AI platform with AstraZeneca's pharmaceutical expertise.
• Osaka HoldingscoreStrategic or Co-development Partner · 20 March 2025Exscientia's over $1 billion merger with BenevolentAI was reported as a significant M&A activity in the sector, though the actual merger was with Osaka Holdings S.à r.l.
• The Institute of Cancer ResearchcoreStrategic or Co-development Partner · 1 June 2020BenevolentAI collaborated with The Institute of Cancer Research to identify drug combinations for DIPG brain cancer using their AI-driven drug repurposing platform.

Recent moves6 records

Expansion highlights4 records

Direct peers

• Exscientia: Direct peer in AI-driven small-molecule drug discovery; both companies combine AI platforms with pharma partnerships to accelerate target identification and molecule design. Exscientia is explicitly named alongside BenevolentAI in sector coverage and itself underwent a merger transaction in 2025.
• Insilico Medicine: Direct peer using generative AI and deep learning for end-to-end drug discovery, from target identification through preclinical candidate nomination. Insilico is named in the same next-tier cohort of AI drug discovery specialists as BenevolentAI.
• Recursion Pharmaceuticals: Direct peer applying AI and high-throughput experimental automation to drug discovery; both companies target the same pharma partnership and pipeline economics. Recursion is a US-based comparable in scale and ambition.
• Schrödinger, Inc. Direct peer combining physics-based computational chemistry with AI/ML for drug discovery, serving large pharma customers. Comparable hybrid platform approach and target pharma customer base.
• Atomwise: Direct peer in AI-driven small-molecule drug discovery, particularly virtual screening and hit identification. Comparable technology positioning and pharma collaboration model.
• XtalPi: Direct peer combining AI, quantum physics, and robotics for drug discovery and crystal structure prediction. Comparable platform approach serving global pharma customers.

Broad incumbents

• Isomorphic Labs: Alphabet-owned AI drug discovery lab founded by DeepMind; broader incumbent with deeper capital base pursuing AI-native drug design. Comparable end-market but with significantly larger financial and computational resources.

Emerging players

• Verge Genomics: Emerging player applying AI to genomics-driven drug discovery, with overlap on target identification. Smaller and earlier-stage but competes for similar pharma collaboration and venture capital.
• Owkin: Emerging player applying AI/ML to biomedical research and drug development, with overlap in AI-driven target and biomarker discovery for pharma partners. More health-data focused but adjacent platform.
• Absci: Emerging player combining generative AI with wet-lab validation for biologic and small-molecule drug discovery. Comparable AI-first discovery approach, particularly relevant given BenevolentAI's exploration of biologic and complex-disease targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/benevolent_ai
• Facebookfacebook.com/BenevolentAI
• LinkedInlinkedin.com/company/benevolentai

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries5 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BenevolentAI